De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin

Cancer

Volumn 80, Issue 6, 1997, Pages 1141-1150

  Jonas, Sven ^a,b   Rayes, Nada ^a   Neumann, Ulf ^a   Neuhaus, Ruth ^a   Bechstein, Wolf O ^a   Guckelberger, Olaf ^a   Tullius, Stefan G ^a   Serke, Stefan ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

De novo malignancies; Immunosuppression; Liver transplantation; Lymphoma

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INOLIMOMAB; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOMA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TUMOR; UTERINE CERVIX CARCINOMA IN SITU;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOMA; NEOPLASMS, SECOND PRIMARY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-2; SKIN NEOPLASMS; TACROLIMUS; UTERINE CERVICAL NEOPLASMS;

EID: 0030809592     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1141::AID-CNCR18>3.0.CO;2-8     Document Type: Article

References (30)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplant patients. Transplant Proc 1969;1:106-12.
2. Penn I. Malignancy. Surg Clin North Am 1994;74:1247-57.
3. Geis WP, Iwatsuki S, Molnar Z, Giacchino JL, Kerman RH, Ing TS, et al. Pseudolymphoma in renal allograft recipients. Arch Surg 1978;113:461-6.
4. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971;28:89-98.
5. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:365-472.
6. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion and the lymphoproliferative syndrome in paediatric liver transplantation. Transplant Proc 1991;23:1473-6.
7. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:1346-53.
8. Bird AG, McLachlan SM, Britton S. Cyclosporine A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981;289:300-1.
9. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995;59:1705-9.
10. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6.
11. Neuhaus P, Bechstein WO, Blumhardt G, Wiens M, Lemmens HP, Langrehr JM, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993;55:1320-7.
12. Neuhaus P, Blumhardt G, Bechstein WO, Platz KP, Jonas S, Mueller AR, et al. Comparison of FK506- and cyclospurine-based immunosuppression in primary orthotopic liver transplantation. Transplantation 1995;59:31-40.
13. Melosky B, Karim M, Chui A, McBride M, Cameron EC, Yeung CK, et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992;2(Suppl 3):S290-4.
14. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Fung JJ, McCauley J, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995;59:485-90.
15. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, et al. An increased incidence of Epstein-Barr virus infection and lymphproliferative disorder in in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
16. Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Platz KP, Keck H. Technique and results of biliary reconstruction using side-to-side choledocho-choledochostomy in 300 orthotopic liver transplants. Ann Surg 1994;219:426-34.
17. Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled prospective randomized trial. Clin Transplant 1995;9:406-14.
18. Bechstein WO, Langrehr JM, Lohmann R, Blumhardt G, Lemmens HP, Neuhaus P. Interleukin-2 receptor antibody versus ATG for induction immunosuppression after liver transplantation: results of a prospective randomized trial. Chir Forum 1994;100-2.
19. Schattenfroh N, Lange D, Bechstein WO, Blumhardt G, Keck H, Langrehr JM, et al. Induction therapy with ariti-T-lymphocyte globulin following orthotopic liver transplantation. Transplant Proc 1993;25:2702.
20. Mor E, Solomon H, Gibbs JF, Holman MJ, Goldstein RM, Husberg BS, et al. Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome. Semin Liver Dis 1992;12:28-40.
21. Serke S, Saeuberlich S, Huhn D. Multiparameter flowcytometrical quantitation of circulating CD34+ cells: correlation to the quantitation of circulating haematopoietic progenitor cells by in vitro colony assay. Br J Haematol 1992;77:453-9.
22. + cells. Blood 1991;80:1628-9.
23. Frei U, Bode U, Repp H, Schindler R, Brunkhorst R, Vogt P, et al. Malignancies under cyclosporine after kidney transplantation: analysis of a 10-year period. Transplant Proc 1993;25:1394-7.
24. + B lymphocytes. Transplantation 1995;59:637-40.
25. Robinson E, Rubin D, Mekori T, Segal R, Pollack S. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol Immunother 1993;37:209-12.
26. Wei WZ, Gill RF, Wang H. Mouse mammary tumor virus associated antigens and super antigens - immuno-molecular correlates of neoplastic progression. Semin Cancer Biol 1993;4:205-13.
27. Stewart T, Tsai SCJ, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346:796-8.
28. Multicenter FK506 Liver Study Group. Prognostic factors for successful conversion from cyclosporine to FK506-based immunosuppressive therapy for refractory rejection after liver transplantation. Transplant Proc 1993;25:641-3.
29. Jonas S, Bechstein WO, Lemmens HP, Kling N, Grauhan O, Lobeck H, et al. Conversion to tacrolimus after liver transplantation. Transpl Int 1996;9:23-31.
30. Doyle HR, Marino IR, Morelli F, Doria C, Aldrighetti L, McMjchael J, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg 1996;224:168-77.